19 Mar 2018 EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
19 Mar 2018 Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing Round
17 Mar 2018 FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
16 Mar 2018 First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG
15 Mar 2018 Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
15 Mar 2018 Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
13 Mar 2018 Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
13 Mar 2018 Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
13 Mar 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
12 Mar 2018 All time high of biologics sales in 2017 driven by cancer and innovative anti-inflammatory antibodies
12 Mar 2018 Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
12 Mar 2018 Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
07 Mar 2018 Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
07 Mar 2018 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
07 Mar 2018 Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
07 Mar 2018 Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
07 Mar 2018 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
06 Mar 2018 Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress
06 Mar 2018 Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
03 Mar 2018 Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
02 Mar 2018 TCR-Based Antibodies, Fusion Proteins and Cell-Penetrating Biologics to Tap the Intracellular Target Pool
02 Mar 2018 FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
28 Feb 2018 BioAtla Announces First Patient Treated in CAB-AXL-ADC Phase 1/2 Clinical Trial BA3011-001
28 Feb 2018 Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors
28 Feb 2018 BioAtla Announces First Patient Treated In Phase1/2 BA3011-001 Clinical Trial For CAB-AXL-ADC Therapeutic

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up